Annexin A2 Versus Afp as An Efficient Diagnostic Serum Marker for Hepatocellular Carcinoma

Amany M Ibrahim, Mona E Hashem, Ehab F Mostafa, Mohamed M Refaey, Emad F Hamed, Islam Ibrahim, Mohammad A Almahdy

Abstract


AIM: To assess the annexin A2 versus AFP as an efficient Serum marker for Hepatocellular carcinoma diagnosis. Hepatocellular carcinoma is the third leading cause of cancer-related death, HCC prognosis is poor, and early detection is of the utmost importance. Although serum AFP is a useful biomarker for the detection and monitoring of HCC, the false-negative rate using the AFP level alone may be high. Several biomarkers are under research, one of them is annexin A2 (Annexin11, ANXA2) is a 36 kDa calcium-dependent phospholipid-binding protein that is presented on the surface of most eukaryotic cells, involving in several biological processes. METHODS: 105 patients were included , 70 of them were diagnosed as HCC ,these patients were divided into group 1 early stage HCC (n=37; male=23, female=14), and group 2 late stageHCC(n=43; male=29, female=14) and the other 35 patients (Group 3) were cirrhotics (20 males and15 females) beside that there were about 20 healthy control (Group 4). All subjects underwent a full history, physical examination and investigations, including: liver function tests, viral markers (HCV Ab and HBs Ag), AFP and evaluation of serum annexin A2 level and abdominal ultrasonography. On the other hand abdominal CT(was done for patients groups) and liver biopsy was done for diagnosis of hepatocellular carcinoma (group1). RESULTS: The mean level of serum annexin A2 in HCC patients were significantly higher than in the cases with liver cirrhosis or normal control (P<0.001), while no significant difference between liver cirrhosis and normal control. There was no significant relation with age, gender, S. albumin, S. bilirubin, S.ALT and hepatitis C infection. However there was a significant relation with hepatitis B infection. The specificity and sensitivity of serum annexin A2 and AFP measurements were represented by ROC curves. Area under ROC curve for AFP (AUC) was 0.84 with 0.75 to 0.910, 95% confidence interval with p<0.0001, the AUC for Annexin A2 was 0.89 with 0.81 to 0.95, 95% confidence interval with P<0.0001, AUC for both markers was 0.818 with 0.723 to 0.890, 95% confidence interval with P<0.0001, when comparing the sensitivity and specificity of annexin A2 with AFP or both markers they were; (78% & 91% for annexin A2 and 70.1% & 65.5% for AFP and 91.9% & 63.6% for both). CONCLUSION: Serum level of annexin A2 can be a good marker for HCC, with higher sensitivity, specificity, positive and negative predictive value than AFP. Complementary diagnostic value was achieved by measuring both annexinA2 &AFP for HCC diagnosis, we found sensitivity and negative predictive value were higher than in either both.

Keywords


Annexin; Marker; Hepatocellular carcinoma

References


Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.

Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90

Thompson Coon J, Rogers G, Hewson P, Wright D,

Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein

K. Surveillance of cirrhosis for Hepatocellular carcinoma:

systematic review and economic analysis. Health Technol

Assess 2007; 11: 201–206

Velázquez RF, Rodríguez M, Navascués CA, Linares A,

Pérez R, Sotorríos NG, Martínez I, Rodrigo L. Prospective

analysis of risk factors for hepatocellular carcinoma in

patients with liver cirrhosis. Hepatolog 2003; 37: 520-527

Inas Elattar : Website of the National Cancer Institute,

Egypt: http:// www.nci.edu.eg; 2003.

El-Zayadi AR, Badran HM, Barakat EM, Attia Mel-D,

Shawky S, Mohamed MK, Selim O, Saeid A. Hepatocellular

carcinoma in Egypt: A single center study over a decade.

World J Gastroenterol 2005; 11: 5193-5198

Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ,

Chappell CL, Beasley RP, Hwang LY. The role of hepatitis C

in hepatocellular carcinoma: a case control among Egyptian

patients. J Clin Gastroenterol 2001; 33: 123-126

Freedman LS, Edwards BK, Ries LAG, Young JL, eds.

Cancer incidence in four member countries (Cyprus, Egypt,

Israel, and Jordan) of the middle east cancer consortium

(MECC) compared with US SEER. National Cancer Institute.

Bethesda, MD: NIH Pub, 2006; No. 06-5873.

National Cancer Registry of Egypt. Magnitude of

hepatocellular carcinoma in Egypt. Available at: http://

www.nci.edu.eg. Accessed 6 August 2010.

Egyptian Ministry of Health. Egyptian Ministry of Health

Annual Report: 2007. Available at: http://www.mohp.gov.

eg/ Main.asp (accessed 6 July 2010).

Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid

M, Gamil F, Madkour S, Mikhail NN, Thomas D, Fix AD,

Strickland GT, Anwar W, Sallam I. Hepatitis C virus (HCV)

infection in a community in the Nile Delta: population

description and HCV prevalence. Hepatology 2000; 32 :

-115

K h a t t a b M A , E s l a m M , S h a r w a e M A , H a m d y L .

Seroprevalence of hepatitis C and B among blood donors

in Egypt: Minya Governorate, 2000-2008. Am J Infect Control

; 38(8): 640-641

El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;

: 1118–1127

De Masi S, Tosti ME, Mele Al. Screening for hepatocellular

carcinoma. Dig Liver Dis 2005; 37: 260–268.

Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS,

Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin,

and lectin-bound alpha-feto-protein in early

hepatocellular carcinoma. Gastroenterology 2009; 137: 110–

Malaguarnera G, Giordano M, Paladina I, Berretta M,

Cappellani A. Serum markers of hepatocellular carcinoma.

Dig Dis Sci 2010; 55: 2744–2755

Lokman AN, Ween PM, Oehler KM and Ricciardelli C.

The Role of Annexin A2 in Tumorigenesis and Cancer

Progression. Cancer Microenvironment 2011; 4: 199–208

Hajjar KA and Krishnan S. Annexin II: A mediator of the

plasmin/plasminogen activator system. Trends Cardiovasc

Med 1999; 9: 128-138

Hajjar KA, Guevara CA, Lev E, Dowling K and Chacko J.

Interaction of the fibrinolytic receptor, annexin II, with the

endothelial cell surface. Essential role of endonexin repeat 2.

J Biol Chem 1996; 271: 21652-21659.

Mai J, Waisman DM, Sloane BF. Cell surface complex of

cathepsin B/annexin II tetramer in malignant progression.

Biochim Biophys Acta 2000; 1477: 215–230

Vishwanatha JK, Chiang Y, Kumble KD, Hollingsworth MA

and Pour PM. Enhanced expression of annexin II in human

pancreatic carcinoma cells and primary pancreatic cancers.

Carcinogenesis 1993; 14: 2575–2579

Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP,

Sharma MC. Angiogenesis associated protein annexin II in

breast cancer: selective expression in invasive breast cancer

and contribution to tumor invasion and progression. Exp

Mol Pathol 2006; 81: 146–156

Mohammad HS, Kurokohchi K, Yoneyama H, Tokuda

M, Morishita A, Jian G, Shi L, Murota M, Tani J, Kato K,

Miyoshi H, Deguchi A, Himoto T, Usuki H, Wakabayashi H,

Izuishi K, Suzuki Y, Iwama H, Deguchi K, Uchida N, Sabet

EA, Arafa UA, Hassan AT, El-Sayed AA, Masaki T. Annexin

A2 expression and phosphorylation are up-regulated in

hepatocellular carcinoma. Int J Oncol,2008; 33: 1157–1163

Inokuchi J, Narula N, Yee DS, Skarecky DW, Lau A,

Ornstein DK, Tyson DR. Annexin A2 positively contributes

to the malignant phenotype and secretion of IL-6 in DU145

prostate cancer cells. Int J Cancer 2009; 124: 68–74

Tchagang AB, Tewfik AH, DeRycke MS, Skubitz KM,

Skubitz AP. Early detection of ovarian cancer using group

biomarkers. Mol Cancer Ther 2008; 7: 27–37

Zhao P, Zhang W, Tang J, Ma XK, Dai JY, Li Y, Jiang JL,

Zhang SH, Chen ZN. Annexin II promotes invasion and

migration of human hepatocellular carcinoma cells in vitro

via its interaction with HAb18G/CD147. Cancer Sci 2010;

: 387-395

Lokman NA, Ween MP, Oehler MK, Ricciardelli C. The role

of annexin A2 in tumorigenesis and cancer progression.

Cancer Microenviron, 2011; 4: 199-208.

Madureira PA, Surette AP, Phipps KD, Taboski MA,

Miller VA, Waisman DM. The role of the annexin A2

heterotetramer in vascular fibrinolysis. Blood 2011; 118:

-4797

Nahon P, Sutton A, Pessayre D, Rufat P, Degoul F, Ganne-

Carrie N, Ziol M, Charnaux N, N'kontchou G, Trinchet

JC, Gattegno L, Beaugrand M. Genetic dimorphism in

superoxide dismutase and susceptibility to alcoholic

cirrhosis, hepatocellular carcinoma and death. Clin

Gastroenterol Hepato 2005; 3(3): 292-298

Clinical Practice Guidelines. Journal of Hepatology 2012; 56:

–943

Zhou L, Liu J and Luo F. Serum tumor markers for detection

© 2013 ACT. All rights reserved. 784

Ibrahim AM et al . Annexin as a marker for HCC

of hepatocellular carcinoma. World J Gastroenterol 2006; 12:

-1181

Joseph BL. Recent developments in the first detection of

hepatocellular carcinoma. Clin Biochem Rev, 2005; 26:

-79.

Yuen MF and Lai CL. Serological markers of liver cancer.

Best Pract Res Clin Gastroenterol 2005; 19: 91-99

Gerke V and Moss SE. Annexins: from structure to function.

Physiol Rev 2002; 82: 331-371.

Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K,

Edil BH, Mizuma M, Sharma R, Le DT, Anders RA, Illei

PB, Van Eyk JE, Maitra A, Laheru D, Jaffee EM. Tyrosine

phosphorylation-dependent cell-surface localization

of annexin A2 is required for invasion and metastases of

pancreatic cancer. PLoS One 2011; 6: e19390

Sun Y, Gao G, Cai J, Wang Y, Qu X, He L, Liu F, Zhang

Y, Lin K, Ma S, Yang X, Qian X, Zhao X. Annexin A2 is

a discriminative serological candidate in early hepatocellular

carcinoma. Carcinogenesis 2012; vol. 00 no.00 p.1 of

Sharma M, Ownbey RT, Sharma MC. Breast cancer

cell surface annexin II induces cell migration and

neoangiogenesis via tPA dependent plasmin generation.

Exp Mol Pathol, 2010; 88: 278-286

Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K,

Tachibana M. Annexin II represents metastatic potential in

clear-cell renal cell carcinoma. Br J Cancer 2009; 101: 287-294

Zhao P, Zhang W, Tang J, Ma XK, Dai JY, Li Y, et al. Annexin

II promotes invasion and migration of human hepatocellular

carcinoma cells in vitro via its interaction with

HAb18G/CD147. Cancer Sci 2010; 101: 387-395

Sun Y, Gao G, Cai J, Wang Y, Qu X, He L, Liu F, Zhang

Y, Lin K, Ma S, Yang X, Qian X, Zhao X. Expression

characteristics and diagnostic value of annexin A2 in

hepatocellular carcinoma. World J Gastroenterol 2012;

November 7; 18(41): 5897-5904

Yoon SY, Kim JM, Oh JH, Jeon YJ, Lee DS, Kim JH, Choi

JY, Ahn BM, Kim S, Yoo HS, Kim YS, Kim NS. Gene

expression profiling of human HBV- and/or HCVassociated

hepatocellular carcinoma cells using expressed

sequencetags. Int J Oncol, 2006; 29: 315–327

Feng H, Feng H, Li X, Niu D, Chen WN. Protein profile in

HBx transfected cells: a comparative iTRAQ-coupled 2D

LC-MS/MS analysis. J Proteomics 2010; 73: 1421–1432

Ji NY, Park MY, Kang YH, Lee CI, Kim DG, Yeom YI, Jang

YJ, Myung PK, Kim JW, Lee HG, Kim JW, Lee K, Song EY.

Evaluation of annexin II as a potential serum marker for

hepato-cellular carcinoma using a developed sandwich

ELISA method. International Journal of Molecular Medicine

; 24: 765-771


Full Text: PDF HTML

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.